It has been shown that, similar to CD8+ cells, CD4+ cells harboring human MHC class I- restricted specific TCRs exhibit anti-tumor activity in vivo and in vitro and are suggested to be as efficacious as CD8+ T cells [27], [28]. This evidence concerns the gene CD4 and neoplasm.